Kodiak Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
KOD$108.06+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(132,102) | $(200,975) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation | 14,084 | 13,572 |
| Stock-based compensation | 51,594 | 65,727 |
| Net amortization (accretion) of premium (discount) on marketable securities | — | (846) |
| Settlement of derivative contracts | 355 | (314) |
| Amortization of operating lease right-of-use asset | 5,940 | 5,711 |
| Amortization of issuance costs | — | 4 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (827) | 6,994 |
| Other assets | (24) | 410 |
| Accounts payable | (10,330) | 3,114 |
| Accrued and other current liabilities | (7,779) | (8,263) |
| Operating lease liability | (8,160) | (7,078) |
| Net cash provided by (used in) operating activities | (87,249) | (121,944) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (251) | (13,866) |
| Deposits on property and equipment | (25) | (77) |
| Purchase of marketable securities | — | (49,347) |
| Maturities of marketable securities | — | 340,000 |
| Settlement of derivative contracts | (355) | 314 |
| Net cash provided by (used in) investing activities | (631) | 277,024 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock upon options exercise | 38 | 60 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 59 | 131 |
| Principal payments of tenant improvement allowance payable | — | (36) |
| Net cash provided by (used in) financing activities | 97 | 155 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (87,783) | 155,235 |
| Cash, cash equivalents and restricted cash, at beginning of period | 291,831 | 196,757 |
| Cash, cash equivalents and restricted cash, at end of period | $204,048 | $351,992 |
| Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets | ||
| Cash and cash equivalents | $197,864 | $345,668 |
| Restricted cash | 6,184 | 6,324 |
| Total cash, cash equivalents and restricted cash in consolidated balance sheets | $204,048 | $351,992 |
| Supplemental disclosures of non-cash investing and financing information: | ||
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $(49) | $2,668 |
| Purchase of property and equipment under accounts payable and accruals | $14 | $27,465 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.